logo-loader
ImmuPharma PLC

Notice of AGM and posting of Report & Accounts

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;text-decoration:underline;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .bh{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 53.95pt 90.0pt;}div.bh{}p.cd{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold}span.cb{color:black}p.ce{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: center}p.cf{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; text-align: center}p.cg{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";background:white}p.ch{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify}table.ci{margin-left:-10.8pt;border-collapse:collapse}td.bm{width:455.3pt;padding:0cm 5.4pt 0cm 5.4pt} table.cj{border-collapse:collapse}td.bu{width:294.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.ck{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}td.bt{width:194.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.cl{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify; text-autospace:ideograph-numeric ideograph-other}p.cm{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: justify; text-autospace: ideograph-numeric ideograph-other}span.cn{color:blue;color:windowtext;text-decoration:none}p.co{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-right:-5.4pt;text-align:justify}p.cp{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;margin-left:7.1pt;text-align:justify}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";} span.bj{font-size:10.0pt;line-height:107%;font-family:"Times New Roman","serif"}br.bk{page-break-before:always}p.cq{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:8.0pt;line-height:107%;punctuation-wrap: hanging;text-autospace:ideograph-numeric ideograph-other} /**/
RNS Number : 9079A
Immupharma PLC
04 June 2019
 

                                                                                                                                                          4 JUNE 2019

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Notice of AGM and posting of Report & Accounts

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2018, and the Notice of Annual General Meeting has been posted to shareholders.

 

These documents are available, in electronic form, for download on the Company's website www.immupharma.co.uk.

 

ImmuPharma's Annual General Meeting will be held on Thursday 27 June at 10:30am (BST) at the offices of: Capital Access Group, 107 Cheapside, London, EC2V 6DN.

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

+ 44 (0) 207 152 4080

Tim McCarthy, Chairman

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DOCUORWRKOANRRR

Quick facts: ImmuPharma PLC

Price: £0.10

Market: AIM
Market Cap: £17.15 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly...

6 days, 9 hours ago